Cell therapy is the third core track driving the iteration and upgrading of the biopharmaceutical industry, following small molecule chemical drugs and antibody drugs. Relying on
Introduction On July 21-22, the “Pharmaceutical BD Intellectual Property Due Diligence Practice Forum,” hosted by IP Link, was successfully held in Shanghai. Tang Huadong, partner at Merits
Introduction: In 2026, domestic pharmaceutical innovation will enter a critical period of accelerated iteration. Patent examination has become increasingly strict, major drugs are expiring in concentrated
This week, multiple findings were announced in biomedicine: aging research revealed that abnormal EP2 signaling in macrophages is the core trigger, and clearing senescent neutrophils can reverse
financing, and financing saw multiple financing and BD deals in the AI biotechnology sector this week. Westlake Omi received strategic investment, accelerating the commercialization of its AI
Introduction: On July 16, the Beijing Intellectual Property Court held a public hearing for a highly publicized trademark administrative dispute case. The plaintiff is luxury giant
Introduction: The UK exosome delivery platform is open to global collaboration, focusing on exosome loading and delivery for RNA, protein, gene therapy, and gene editing payloads,
· Macao SAR Innovation Entities Approved to be Included in the Patent Pre - examination Service Scope of Zhuhai Intellectual Property Protection Center · European Patent
In recent years, as China-US relations have evolved, compliance considerations in cross-border transactions have become increasingly important. On April 27, 2026, the Office of the Foreign
– Introduction – This issue compiles five cutting-edge innovative projects in the medical and health field, covering ophthalmic nanoemulsion delivery platforms, visual lung isolation dual-branch systems, heart